Treatment guide · Joint pain / tendon injuries / compare treatments
I received PRF and exosomes for several painful areas and noticed a major improvement. Here is how the evidence for PRF compares with PRP for joint and tendon problems.
PRP has a larger musculoskeletal research base than PRF, but results depend on the condition and preparation. Knee osteoarthritis trials are mixed, and substantial placebo-controlled trials have not shown a statistically significant advantage for Achilles tendinopathy or tennis elbow. Direct human PRP-versus-PRF studies exist, but they do not establish a general winner. Neither treatment can promise cartilage regrowth or repair of a torn ligament.
Ask which preparation has human evidence for your diagnosis, what rehabilitation the course includes and how you and the clinician will judge whether treatment helped.
My treatment combined PRF and exosomes. I noticed a major improvement across several painful areas. I cannot separate the effect of PRF from the exosomes, and this was not a comparison with PRP.
My experience cannot tell another patient which injection will work, how long a benefit will last or whether damaged tissue has healed. Our SLS profile records the treatment course and cost; our exosome guide examines that separate evidence base.
PRP means platelet-rich plasma. A clinician takes blood and processes it to concentrate platelets in plasma. Platelets release proteins involved in injury responses, including growth factors. Preparations can contain different amounts of platelets and white blood cells. Those differences are part of the treatment, even when every clinic calls it PRP. [1]
PRF means platelet-rich fibrin. The term covers several preparations involving fibrin, the protein network that forms during clotting. Injectable PRF, or i-PRF, is collected while still liquid and subsequently forms a fibrin network. In commonly studied protocols it is prepared without an anticoagulant, while PRP usually uses one. That is a description of those protocols, not a rule covering every product sold under either name. [2]
| Preparation | What the name tells you | What still needs checking |
|---|---|---|
| PRP | Platelets concentrated in plasma. | Platelet dose, white-cell content, activation and injection protocol. [1, 2] |
| Injectable PRF (i-PRF) | A liquid PRF preparation that forms fibrin. | Collection method, composition and time between preparation and injection. [2] |
| Platelet-rich fibrin matrix (PRFM) | A platelet-containing fibrin matrix, including products used during surgery. | The actual preparation and application; a surgical matrix trial does not test every injectable PRF product. [3] |
| Albumin-PRF (ALB-PRF) | A preparation incorporating heat-coagulated albumin gel. | Whether it is combined with other platelet preparations, and which combination was studied. [4] |
Knee osteoarthritis has substantial PRP research, including placebo-controlled trials with conflicting results. In the 2021 RESTORE trial, 288 adults received PRP or saline. At 12 months, PRP did not significantly improve the primary outcomes of knee pain or medial tibial cartilage volume compared with saline. Both groups reported less pain. [5]
A multicenter trial published in 2022 reported a different result. Among 610 participants who completed the trial, three PRP injections produced better pain and function outcomes than saline at several follow-ups. The authors reported sustained symptom benefits. This is evidence in favor of the protocol they tested, rather than a guarantee for any preparation offered elsewhere. [6]
Guidelines reflect that uncertainty. The 2021 AAOS guideline says PRP may improve knee pain and function, but rates the recommendation as limited because of inconsistent evidence. The 2026 VA/DoD guideline finds insufficient evidence to recommend for or against PRP for persistent knee osteoarthritis pain. These are different judgments about a mixed literature. [7, 8]
For a patient, the useful question is whether a proposed PRP course offers a worthwhile chance of symptom relief after discussing established care. A clinic should explain why its protocol is relevant to your diagnosis and arthritis severity. A trial reporting less pain is not evidence that your cartilage will regrow, and PRF cannot inherit PRP's knee results simply because both come from blood.
A 2021 JAMA trial enrolled 240 people with chronic midportion Achilles tendinopathy. A single PRP injection into the tendon did not improve tendon-related pain and function more than a sham procedure at six months. Discomfort at the injection site was common. [9]
The diagnosis matters here. Chronic midportion tendinopathy, pain where the tendon attaches to the heel and an acute Achilles rupture are different problems. This trial tested one defined condition and protocol. It offers no basis for promising that a PRP tendon injection will fix every painful Achilles, and it does not establish that PRF would perform better.
Before paying, ask which tissue is causing the pain, what rehabilitation has been tried and what finding would change the plan. A vague promise to treat inflammation is not enough to compare an injection with a structured rehabilitation program.
Tennis elbow is a useful example of why improvement after an injection needs a comparison group. In a randomized trial of 119 people, PRP and autologous whole-blood injections did not outperform saline for pain or function at one year. All three groups improved over time. [10]
PRF has encouraging observational findings. A 2024 report by Torbjörn Ogéus described 528 patients with lateral epicondylitis treated with PRF preparations and heat-coagulated albumin gel. Pain scores improved during follow-up. However, the study was retrospective, had no comparison group and excluded patients with incomplete follow-up or poor rehabilitation adherence. The course included rehabilitation. [4]
That report can justify further controlled research. It cannot show whether PRF outperforms PRP, whether the albumin component adds benefit or how much of the improvement came from the injections. It also studied a PRF-based combination, not exosomes. A large patient count does not remove those limits.
Direct human comparisons have tested PRP and PRF for particular diagnoses. Their findings need to be read alongside the preparation used and the study design.
A 2019 study compared injectable PRF in 124 people with PRP in 62 people with sacroiliac joint dysfunction. Pain scores favored PRF at six months, but assignment was not randomized. Differences between the groups may therefore have affected the result. This is evidence about sacroiliac pain, not a trial of knee cartilage or tendon repair. [11]
A small 2026 randomized trial compared leukocyte-rich PRP, leukocyte-poor PRP, i-PRF and corticosteroid for frozen shoulder. There were 64 participants, only 16 per group. The platelet groups had better reported longer-term outcomes than the steroid group; i-PRF and leukocyte-poor PRP performed well at 12 months. The study was conducted at one center and had no placebo group. [12]
These studies do not establish that PRF is generally better than PRP. Nor does the shoulder trial establish superiority for rotator cuff tears: frozen shoulder involves restricted joint movement and is a different diagnosis. If a clinic cites a favorable comparison, read the condition in the title before accepting the sales conclusion.
A PRP shoulder injection can refer to treatment of several different structures. Evidence from frozen shoulder should not be presented as proof that an injection repairs a torn rotator cuff. In a randomized study of 60 patients undergoing rotator cuff surgery, adding a platelet-rich fibrin matrix did not improve the main clinical or structural outcomes compared with surgery alone. That result concerns the tested surgical matrix, not every PRF preparation. [3]
The same distinction applies to ligaments. Less pain does not establish restored stability or a healed tear. Ask whether the proposed treatment is intended to relieve symptoms, assist rehabilitation or change a structural outcome, and what evidence supports that particular aim. An injection should not delay assessment of an unstable joint or a suspected tendon or ligament rupture.
Ask for the preparation's name and composition rather than accepting a label such as advanced PRF. A 2026 laboratory comparison found meaningful differences between the tested leukocyte-rich PRP and i-PRF protocols. It measured blood products, not patient recovery. More platelets, a different fibrin structure or a longer release curve cannot by itself prove a better clinical result. [2]
AAPM&R's clinical guidance for knee osteoarthritis emphasizes patient selection, preparation characteristics, administration and rehabilitation. The guidance combines a structured evidence review with expert consensus; it should not be read as a promise of success. [13]
Before treatment, agree on what improvement would mean in daily life: walking stairs, lifting a bag, returning to a specific exercise or needing less pain medication. Record the starting point and the planned review date. If several areas and several treatments are addressed together, track each area separately. Otherwise it becomes difficult to decide what helped and whether another course is worthwhile.
Using your own blood does not make a procedure risk-free. PRP injections can cause a temporary pain flare, and injection procedures carry risks including infection and injury to nearby tissue or nerves. Discuss the risks for the actual injection site and preparation. A small PRF study reporting no serious complications cannot rule out uncommon harms. [1]
Get written instructions for activity, rehabilitation and follow-up. Tell the clinician about your medications and medical conditions. Do not stop prescribed medication to follow an online preparation checklist; medication changes belong with the prescriber and treating clinician.
Compare the complete course price: assessment, imaging if needed, preparation, injections, follow-up and rehabilitation. Ask what happens if you do not improve. Avoid using my combined PRF-and-exosome bill as a PRF price benchmark: it covered a different course with several treatment areas.
What is my diagnosis, and which structure would you inject? Which preparation will you use, and which human study best matches this condition and protocol? What benefit would be realistic, and how will we measure it? What rehabilitation and follow-up are included?
Ask the clinician to explain the alternatives and the consequence of waiting. If the proposal combines PRF, PRP, exosomes or another procedure, request a reason for each component and evidence for the combination. Agree in advance on when to reassess the diagnosis instead of automatically purchasing more injections.
We reviewed primary human studies and professional guidance available on October 25, 2026. This is a focused editorial review, not a systematic review. We distinguish randomized comparisons from uncontrolled reports and laboratory findings, and keep each finding tied to the condition and preparation studied.
Written by David Persson, Agewell’s founder, who received PRF and exosome treatment. He is not a physician. No medical reviewer is credited for this article. There are no treatment-booking or affiliate links in this guide.
No general advantage has been established. Direct studies in sacroiliac pain and frozen shoulder have reported favorable PRF results, but their designs and small or nonrandomized groups limit the conclusion. They cannot establish which treatment is best for a different joint or diagnosis. [11, 12]
Reliable cartilage regrowth is not an established outcome to expect from PRP. Trials report conflicting symptom and structural findings; RESTORE found no significant benefit for its primary cartilage-volume outcome at 12 months. Pain relief and new cartilage are different outcomes. [5, 6]
No. PRF is a blood-derived fibrin preparation. Exosome products are preparations of extracellular vesicles and have a separate evidence base. My treatment included both, so my improvement cannot establish the effect of either one alone.
There is no single schedule supported across all conditions and preparations. Ask why the proposed number and spacing match your diagnosis, which study supports that course and when the clinician would stop or revise treatment.
There is no dependable timetable for an individual patient. Studies assess different preparations and conditions over weeks or months, and some find no added benefit. Agree on a review date and functional goals rather than accepting a guaranteed recovery date.
By David Persson · Updated 2026-10-25 · Corrections: hi@agewell.guide
The Agewell Briefing
A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.
One email a week. Unsubscribe with one click.
